The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis

Sekiguchi, Kenji; Sumi, Minako; Saito, Anneyuko I.; Zenda, Sadamoto; Arahira, Satoko; Iino, Keiko; Okumura, Masayuki; Kawai, Fujimi; Nozawa, Keiko

doi:10.1007/s12282-022-01403-8

Cited by 8 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, moisturizing was effective in managing xerosis in a small ( n = 30) uncontrolled trial of cancer patients [ 29 ]. More recently, a systematic review concluded that moisturizer use reduced the occurrence of severe acute radiation dermatitis and there was weak evidence indicating moisturizer use improved quality of life [ 30 ]. Patients should also be educated to avoid harsh soaps and basic pH cleansers, limit shower time and avoid hot water, and frequently apply emollients [ 1 , 3 ].…”

Section: Recommendationsmentioning

confidence: 99%

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

Dreno,

Khosrotehrani,

De Barros Silva

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions (cytotoxic chemotherapy, targeted therapies, immunotherapy, and radiotherapy). Further, skin toxicities can lead to interruption or even discontinuation of anticancer treatment in some patients, translating to suboptimal outcomes. Dermocosmetics (or cosmeceuticals)—defined as skincare solutions incorporating dermatologically active ingredients (beyond vehicle effects) that directly improve symptoms of various skin conditions—are increasingly being used in cancer care to prevent and manage skin toxicities. The active ingredients in these products have a measurable biological action in skin; they typically improve skin integrity (barrier function/hydration and other factors) while relieving skin symptoms. The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) partnered to select a multidisciplinary group of healthcare professionals involved in the management of patients with cancer and skin toxicities. The group reviewed existing literature and created a summary of recommendations for managing these toxicities through online meetings and communication. In this publication, the group (1) reviews new skin toxicities seen with oncology drugs and (2) evaluates the role of dermocosmetics in improving patient outcomes and minimizing cancer treatment interruptions. We provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.

show abstract

Section: Recommendationsmentioning

confidence: 99%

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

Dreno,

Khosrotehrani,

De Barros Silva

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The most common adverse event associated with thoracic cancer radiotherapy is radiation-induced dermatitis 10 (RID), especially in supraclavicular region. RID might manifest as an initial transient erythema that can occur within the first 24 h after RT.…”

Section: Introductionmentioning

confidence: 99%

“…RID might manifest as an initial transient erythema that can occur within the first 24 h after RT. With the cumulative radiation dose reaches 18–20 Gy, dry desquamation can develop 10 . While moist desquamation can be seen when RT dose higher than 40 Gy, which is more severe and painful 10 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial

Xie,

Jia,

Xie

et al. 2023

Sci Rep

View full text Add to dashboard Cite

To evaluate the safety and effectiveness of epigallocatechin-3-gallate (EGCG) solution treating the acute severe dermatitis in patients receiving radiotherapy. This phase I research enrolled patients with thoracic cancer receiving radiotherapy at Shandong Cancer Hospital and Institute in Shandong, China. EGCG solution was sprayed to the radiation field when grade III radiation-induced dermatitis (RID) first appearance. EGCG concentration escalated from 660 to 2574 μmol/L using modified-Fibonacci dose-escalation. RID and related symptoms were followed up every day. Between March 2021 and November 2021, 19 patients were enrolled in this phase I research. The median dose of grade III RID first observation was 44 Gy (30.6–52 Gy). As the EGCG treatment was performed continuously, all these grade III RID reactions were significantly decreased to grade I or grade II RID at three days after use of EGCG (p < 0.001). Significant relief can be observed in burning sensation (p < 0.001), tractive sensation (p < 0.001), tenderness (p < 0.001), erythema (p < 0.001), itching (p < 0.001) and pain (p < 0.001) after 15 days of EGCG treatment. No radiation therapy delay or interruption for all 19 patients. No adverse events were observed and reported associated with EGCG. The highest dose of this Phase I trial (2574 μmol/L) was recommended for continuous Phase II trial for further evaluation. In this phase I clinical research, use of EGCG solution is safe and can significantly relief grade III RID in patients receiving radiotherapy. Thus, EGCG might be a new choice for acute sever RID.Trial Registration: ClinicalTrials.gov Identifier: NCT02580279 (Full date of first registration: 12/2014).

show abstract

Decrease of radiation-induced skin reactions in breast cancer patients by preventive application of film dressings—a systematic review

Kraemer,

Momm

2023

Strahlenther Onkol

View full text Add to dashboard Cite

The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis

Cited by 8 publications

References 29 publications

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus

Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial

Decrease of radiation-induced skin reactions in breast cancer patients by preventive application of film dressings—a systematic review

Contact Info

Product

Resources

About